2024
Sacubitril/Valsartan in Patients Hospitalized With Decompensated Heart Failure
Morrow D, Velazquez E, Desai A, DeVore A, Lepage S, Park J, Sharma K, Solomon S, Starling R, Ward J, Williamson K, Zieroth S, Hernandez A, Mentz R, Braunwald E. Sacubitril/Valsartan in Patients Hospitalized With Decompensated Heart Failure. Journal Of The American College Of Cardiology 2024, 83: 1123-1132. PMID: 38508844, DOI: 10.1016/j.jacc.2024.01.027.Peer-Reviewed Original ResearchConceptsWorsening heart failureHeart failureEjection fractionNT-proBNPSpectrum of EFPIONEER-HFSpectrum of left ventricular ejection fractionRandomized trialsTime-averaged proportional changeN-terminal pro-B-type natriuretic peptidePro-B-type natriuretic peptideLeft ventricular ejection fractionWorsening heart failure eventDecompensated heart failureVentricular ejection fractionPlasma NT-proBNPPIONEER-HF trialDouble-blindMedian ageMedian EFSNatriuretic peptideSymptomatic hypotensionBaseline characteristicsClinical outcomesPooled analysis
2023
Rationale, Design and Baseline Characteristics of the PARAGLIDE-HF Trial: Sacubitril/Valsartan vs Valsartan in HFmrEF and HFpEF With a Worsening Heart Failure Event
Mentz R, Ward J, Hernandez A, Lepage S, Morrow D, Sarwat S, Sharma K, Solomon S, Starling R, Velazquez E, Williamson K, Zieroth S, Braunwald E. Rationale, Design and Baseline Characteristics of the PARAGLIDE-HF Trial: Sacubitril/Valsartan vs Valsartan in HFmrEF and HFpEF With a Worsening Heart Failure Event. Journal Of Cardiac Failure 2023, 29: 922-930. PMID: 36796671, DOI: 10.1016/j.cardfail.2023.02.001.Peer-Reviewed Original ResearchConceptsSac/ValSacubitril/valsartanHeart failure eventsPARAGON-HF trialWHF eventNT-proBNPEjection fractionHeart failureClinical outcomesAmino-terminal pro-B-type natriuretic peptide levelsTerminal pro-B-type natriuretic peptide levelsB-type natriuretic peptide levelsDe novo HFChronic heart failureNatriuretic peptide levelsPrimary efficacy endpointPg/mLEfficacy endpointSafety endpointSecondary endpointsSymptomatic hypotensionBaseline characteristicsRenal functionStable patientsBlack patients
2017
Sudden cardiac death after acute heart failure hospital admission: insights from ASCEND‐HF
Pokorney SD, Al‐Khatib S, Sun J, Schulte P, O'Connor CM, Teerlink JR, Armstrong PW, Ezekowitz JA, Starling RC, Voors AA, Velazquez EJ, Hernandez AF, Mentz RJ. Sudden cardiac death after acute heart failure hospital admission: insights from ASCEND‐HF. European Journal Of Heart Failure 2017, 20: 525-532. PMID: 29266564, DOI: 10.1002/ejhf.1078.Peer-Reviewed Original ResearchConceptsSudden cardiac deathVT/VFHeart failure hospital admissionsAcute HFCardiac deathHospital admissionVentricular tachycardia/ventricular fibrillationDecompensated Heart Failure (ASCEND-HF) trialChronic obstructive pulmonary diseaseVT/VF eventsEvent ratesComposite event rateMeier event ratesHeart Failure TrialCause mortality ratesDay of admissionObstructive pulmonary diseaseLonger QRS durationCause mortalityBaseline characteristicsComposite endpointEjection fractionPulmonary diseaseASCEND-HFFailure TrialLeft ventricular global longitudinal strain in patients with heart failure with preserved ejection fraction: outcomes following an acute heart failure hospitalization
Buggey J, Alenezi F, Yoon HJ, Phelan M, DeVore AD, Khouri MG, Schulte PJ, Velazquez EJ. Left ventricular global longitudinal strain in patients with heart failure with preserved ejection fraction: outcomes following an acute heart failure hospitalization. ESC Heart Failure 2017, 4: 432-439. PMID: 29154416, PMCID: PMC5695196, DOI: 10.1002/ehf2.12159.Peer-Reviewed Original ResearchConceptsAcute heart failure hospitalizationVentricular global longitudinal strainAbnormal LV-GLSLV-GLSHeart failure hospitalizationGlobal longitudinal strainAcute HFpEFFailure hospitalizationEjection fractionHeart failureLongitudinal strainCox proportional hazards modelDuke University Medical CenterComposite of mortalityMedian LV-GLSWorse LV-GLSChronic heart failureWorse clinical outcomesMyocardial systolic dysfunctionSpeckle-tracking analysisProportional hazards modelUniversity Medical CenterMultivariable adjustmentSystolic dysfunctionBaseline characteristics
2015
Influence of Baseline Characteristics, Operative Conduct, and Postoperative Course on 30-Day Outcomes of Coronary Artery Bypass Grafting Among Patients With Left Ventricular Dysfunction
Wrobel K, Stevens SR, Jones RH, Selzman CH, Lamy A, Beaver TM, Djokovic LT, Wang N, Velazquez EJ, Sopko G, Kron IL, DiMaio JM, Michler RE, Lee KL, Yii M, Leng CY, Zembala M, Rouleau JL, Daly RC, Al-Khalidi HR. Influence of Baseline Characteristics, Operative Conduct, and Postoperative Course on 30-Day Outcomes of Coronary Artery Bypass Grafting Among Patients With Left Ventricular Dysfunction. Circulation 2015, 132: 720-730. PMID: 26304663, PMCID: PMC4551105, DOI: 10.1161/circulationaha.114.014932.Peer-Reviewed Original ResearchConceptsCoronary artery diseaseCoronary artery bypassLeft ventricular dysfunctionVentricular dysfunctionArtery diseaseArtery bypassBaseline characteristicsMedical therapyOperative conductSevere left ventricular dysfunctionAtrial fibrillation/flutterSevere coronary artery diseaseLeft ventricular ejection fractionGreater operative riskSignificant preoperative predictorsCardiopulmonary bypass timeHigh-risk patientsIschemic heart failureSerious postoperative complicationsVentricular ejection fractionLeft ventricular sizeSurgical ventricular reconstructionGreater clinical benefitCABG populationSTICH trialClinical predictors and outcomes of patients with left ventricular thrombus following ST-segment elevation myocardial infarction
Garber AM, Mentz RJ, Al-Khalidi HR, Shaw LK, Fiuzat M, O’Connor C, Velazquez EJ. Clinical predictors and outcomes of patients with left ventricular thrombus following ST-segment elevation myocardial infarction. Journal Of Thrombosis And Thrombolysis 2015, 41: 365-373. PMID: 26202909, DOI: 10.1007/s11239-015-1252-0.Peer-Reviewed Original ResearchConceptsST-segment elevation myocardial infarctionElevation myocardial infarctionNon-white raceHF severityBaseline characteristicsClinical predictorsHeart failureIndependent predictorsMyocardial infarctionHeart rateCox proportional hazards regression modelProportional hazards regression modelsLeft ventricular thrombusLong-term mortalityOutcomes of patientsVentricular thrombus formationHazards regression modelsHigher heart rateEligible patientsInitial troponinCause mortalityLAD diseaseSTEMI patientsVentricular thrombusTransthoracic echocardiogramTorsemide Versus Furosemide in Heart Failure Patients
Mentz RJ, Buggey J, Fiuzat M, Ersbøll MK, Schulte PJ, DeVore AD, Eisenstein EL, Anstrom KJ, O'Connor C, Velazquez EJ. Torsemide Versus Furosemide in Heart Failure Patients. Journal Of Cardiovascular Pharmacology 2015, 65: 438-443. PMID: 25945862, PMCID: PMC4423558, DOI: 10.1097/fjc.0000000000000212.Peer-Reviewed Original ResearchMeSH KeywordsAcademic Medical CentersAgedComorbidityDatabases, FactualFemaleFurosemideHeart FailureHumansKaplan-Meier EstimateMaleMiddle AgedNorth CarolinaRetrospective StudiesRisk FactorsSex FactorsSodium Potassium Chloride Symporter InhibitorsSulfonamidesTertiary Care CentersTorsemideTreatment OutcomeUltrasonographyConceptsHeart failure patientsFailure patientsEffects of torsemideFurosemide-treated patientsMore comorbiditiesCause mortalityBaseline characteristicsProspective trialHeart failureLoop diureticsResidual confoundingPatientsDuke HospitalFurosemideRisk adjustmentTorsemideMortalityLab databaseComorbiditiesDiureticsHospitalTrials
2014
Sex Differences in Platelet Reactivity and Cardiovascular and Psychological Response to Mental Stress in Patients With Stable Ischemic Heart Disease Insights From the REMIT Study
Samad Z, Boyle S, Ersboll M, Vora AN, Zhang Y, Becker RC, Williams R, Kuhn C, Ortel TL, Rogers JG, O’Connor C, Velazquez EJ, Jiang W, Investigators R. Sex Differences in Platelet Reactivity and Cardiovascular and Psychological Response to Mental Stress in Patients With Stable Ischemic Heart Disease Insights From the REMIT Study. Journal Of The American College Of Cardiology 2014, 64: 1669-1678. PMID: 25323254, PMCID: PMC4752118, DOI: 10.1016/j.jacc.2014.04.087.Peer-Reviewed Original ResearchConceptsMental stress-induced myocardial ischemiaIschemic heart diseaseStable ischemic heart diseaseLeft ventricular ejection fractionPlatelet aggregation responseMental stress taskMental stressTransthoracic echocardiographyPlatelet reactivityStress-induced myocardial ischemiaIschemic ST-segment changesRegional wall motion abnormalitiesAggregation responseStress taskMost baseline characteristicsVentricular ejection fractionHigher baseline depressionLong-term outcomesST-segment changesWall motion abnormalitiesPlatelet aggregation studiesSex differencesBaseline characteristicsBlood pressureEjection fraction
2012
Mechanisms and Predictors of Mitral Regurgitation after High-Risk Myocardial Infarction
Meris A, Amigoni M, Verma A, Thune JJ, Køber L, Velazquez E, McMurray JJ, Pfeffer MA, Califf R, Levine RA, Solomon SD, Investigators V. Mechanisms and Predictors of Mitral Regurgitation after High-Risk Myocardial Infarction. Journal Of The American Society Of Echocardiography 2012, 25: 535-542. PMID: 22305962, PMCID: PMC3501447, DOI: 10.1016/j.echo.2012.01.006.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsAgedAngiotensin-Converting Enzyme InhibitorsCaptoprilDisease ProgressionEchocardiography, Doppler, ColorElectrocardiographyFemaleFollow-Up StudiesHumansMaleMiddle AgedMitral Valve InsufficiencyMonitoring, PhysiologicMultivariate AnalysisMyocardial InfarctionPredictive Value of TestsProspective StudiesReference ValuesReproducibility of ResultsRisk AssessmentROC CurveSeverity of Illness IndexSex FactorsStatistics, NonparametricStroke VolumeTetrazolesTime FactorsValineValsartanVentricular Dysfunction, LeftVentricular RemodelingConceptsHigh-risk myocardial infarctionBaseline mitral regurgitationMitral regurgitationMyocardial infarctionAtrial sizeIndependent predictorsCoaptation depthProgression of MRMitral valve deformationStructural valve diseaseSevere mitral regurgitationFunctional mitral regurgitationIschemic mitral regurgitationGood-quality echocardiogramsMitral annular areaMitral tentingMR degreeLV dysfunctionTenting areaBaseline characteristicsDiastolic functionHeart failureValve diseaseLV remodelingVentricular remodeling
2010
STICH (Surgical Treatment for Ischemic Heart Failure) Trial Enrollment
Jones RH, White H, Velazquez EJ, Shaw LK, Pietrobon R, Panza JA, Bonow RO, Sopko G, O'Connor CM, Rouleau JL. STICH (Surgical Treatment for Ischemic Heart Failure) Trial Enrollment. Journal Of The American College Of Cardiology 2010, 56: 490-498. PMID: 20670760, PMCID: PMC3259709, DOI: 10.1016/j.jacc.2009.11.102.Peer-Reviewed Original ResearchConceptsLow-risk patientsSTICH trialRAR groupBaseline characteristicsCardiac surgeryIschemic cardiomyopathyHigh-risk patientsNumber of patientsCountry of enrollmentSTICH patientsDuke DatabankRandomization groupTrial enrollmentCardiovascular diseaseRisk differencePatientsClinical decisionTrialsSurgeryCardiomyopathyRiskBroader populationEnrollment performanceDeathThirty-second
2009
Usefulness of Beta Blockers in High-Risk Patients After Myocardial Infarction in Conjunction With Captopril and/or Valsartan (from the VALsartan In Acute Myocardial Infarction [VALIANT] Trial)
Califf RM, Lokhnygina Y, Velazquez EJ, McMurray JJ, Leimberger JD, Lewis EF, Diaz R, Murin J, Pfeffer MA. Usefulness of Beta Blockers in High-Risk Patients After Myocardial Infarction in Conjunction With Captopril and/or Valsartan (from the VALsartan In Acute Myocardial Infarction [VALIANT] Trial). The American Journal Of Cardiology 2009, 104: 151-157. PMID: 19576338, DOI: 10.1016/j.amjcard.2009.03.020.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAdrenergic beta-AntagonistsAgedAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsCaptoprilDrug Therapy, CombinationFemaleHumansMaleMiddle AgedMultivariate AnalysisMyocardial InfarctionProspective StudiesRisk AssessmentRisk FactorsSurvival AnalysisTetrazolesTreatment OutcomeValineValsartanConceptsBeta blockersHeart failureMyocardial infarctionBaseline characteristicsAcute Myocardial Infarction trialAngiotensin receptor blocker valsartanCombination of valsartanNonfatal cardiovascular eventsAngiotensin receptor blockersBeta-blocker useMyocardial Infarction trialVentricular systolic dysfunctionHigh-risk patientsRisk of deathSignificant survival advantageCardiovascular eventsSystolic dysfunctionVentricular dysfunctionVentricular functionSurvival advantageLower riskPatientsMortality rateBlockersValsartan
2008
Benazepril plus Amlodipine or Hydrochlorothiazide for Hypertension in High-Risk Patients
Jamerson K, Weber MA, Bakris GL, Dahlöf B, Pitt B, Shi V, Hester A, Gupte J, Gatlin M, Velazquez EJ. Benazepril plus Amlodipine or Hydrochlorothiazide for Hypertension in High-Risk Patients. New England Journal Of Medicine 2008, 359: 2417-2428. PMID: 19052124, DOI: 10.1056/nejmoa0806182.Peer-Reviewed Original ResearchConceptsNonfatal myocardial infarctionCardiovascular eventsNonfatal strokeCardiovascular causesMyocardial infarctionHigh riskEnd pointDihydropyridine calcium channel blockerCurrent U.S. guidelinesComposite of deathDouble-blind trialPrimary end pointPrimary outcome eventSecondary end pointsHigh-risk patientsAbsolute risk reductionRelative risk reductionCalcium channel blockersCombination drug therapySudden cardiac arrestRisk reductionCoronary revascularizationStudy drugAdverse eventsBaseline characteristicsRelation of Mortality to Failure to Prescribe Beta Blockers Acutely in Patients With Sustained Ventricular Tachycardia and Ventricular Fibrillation Following Acute Myocardial Infarction (from the VALsartan In Acute myocardial iNfarcTion trial [VALIANT] Registry)
Piccini JP, Hranitzky PM, Kilaru R, Rouleau JL, White HD, Aylward PE, Van de Werf F, Solomon SD, Califf RM, Velazquez EJ. Relation of Mortality to Failure to Prescribe Beta Blockers Acutely in Patients With Sustained Ventricular Tachycardia and Ventricular Fibrillation Following Acute Myocardial Infarction (from the VALsartan In Acute myocardial iNfarcTion trial [VALIANT] Registry). The American Journal Of Cardiology 2008, 102: 1427-1432. PMID: 19026290, DOI: 10.1016/j.amjcard.2008.07.033.Peer-Reviewed Original ResearchMeSH KeywordsAdrenergic beta-AntagonistsAgedClinical Trials as TopicDeath, Sudden, CardiacDrug PrescriptionsFemaleHospital MortalityHumansIncidenceLogistic ModelsMaleMiddle AgedMultivariate AnalysisMyocardial InfarctionPractice Patterns, Physicians'RegistriesRetrospective StudiesRisk AssessmentRisk FactorsTachycardia, VentricularTime FactorsVentricular FibrillationConceptsSustained VT/ventricular fibrillationVT/ventricular fibrillationBeta-blocker therapyAcute myocardial infarctionHeart failureVentricular fibrillationBeta blockersVentricular tachycardiaMyocardial infarctionAcute beta-blocker therapyOral beta blockadeBeta-blocker useHospital mortality rateSustained ventricular arrhythmiasMultivariable logistic regressionSustained ventricular tachycardiaRelation of mortalityBeta blockadeHospital mortalityHospital deathKillip classificationBaseline characteristicsVentricular arrhythmiasEarly mortalityWorse outcomesRacial Analysis of Patients With Myocardial Infarction Complicated by Heart Failure and/or Left Ventricular Dysfunction Treated With Valsartan, Captopril, or Both
Prisant LM, Thomas KL, Lewis EF, Huang Z, Francis GS, Weaver WD, Pfeffer MA, McMurray JJ, Califf RM, Velazquez EJ. Racial Analysis of Patients With Myocardial Infarction Complicated by Heart Failure and/or Left Ventricular Dysfunction Treated With Valsartan, Captopril, or Both. Journal Of The American College Of Cardiology 2008, 51: 1865-1871. PMID: 18466801, DOI: 10.1016/j.jacc.2007.12.050.Peer-Reviewed Original ResearchMeSH KeywordsAngiotensin II Type 1 Receptor BlockersAngiotensin-Converting Enzyme InhibitorsBiomarkersBlack or African AmericanCaptoprilFemaleHeart FailureHospitalizationHumansIncidenceMaleMiddle AgedMyocardial InfarctionRetrospective StudiesRisk FactorsSystoleTetrazolesUnited StatesValineValsartanVentricular Dysfunction, LeftWhite PeopleConceptsLeft ventricular systolic dysfunctionHeart failureAcute myocardial infarctionMyocardial infarctionBaseline characteristicsAfrican AmericansMyocardial Infarction ComplicatedAngiotensin receptor blockersCoronary risk factorsOutcomes of patientsRecurrent myocardial infarctionVentricular systolic dysfunctionSimilar clinical outcomesHF hospitalizationCardiovascular morbidityCause mortalityReceptor blockersSystolic dysfunctionVentricular dysfunctionCardiovascular mortalityWhite patientsClinical outcomesPoor outcomeVALIANT trialSubgroup analysis
2007
Amiodarone use after acute myocardial infarction complicated by heart failure and/or left ventricular dysfunction may be associated with excess mortality
Thomas KL, Al-Khatib SM, Lokhnygina Y, Solomon SD, Kober L, McMurray JJ, Califf RM, Velazquez EJ. Amiodarone use after acute myocardial infarction complicated by heart failure and/or left ventricular dysfunction may be associated with excess mortality. American Heart Journal 2007, 155: 87-93. PMID: 18082495, DOI: 10.1016/j.ahj.2007.09.010.Peer-Reviewed Original ResearchMeSH KeywordsAgedAmiodaroneCaptoprilCause of DeathDose-Response Relationship, DrugDouble-Blind MethodDrug Administration ScheduleDrug Therapy, CombinationFemaleHeart FailureHumansMaleMiddle AgedMultivariate AnalysisMyocardial InfarctionProbabilityProportional Hazards ModelsReference ValuesRisk AssessmentSeverity of Illness IndexSurvival AnalysisTetrazolesTreatment OutcomeValineValsartanVentricular DysfunctionConceptsVentricular systolic dysfunctionAmiodarone useAcute myocardial infarctionMyocardial infarctionSystolic dysfunctionLeft ventricular systolic dysfunctionPost-acute myocardial infarctionHazard ratio 1.5Higher Killip classTrials of amiodaroneKillip classVentricular dysfunctionBaseline characteristicsCardiovascular mortalityDiabetes mellitusHeart failureMedical regimenRandomized comparisonBaseline predictorsExcess mortalityCox modelSubsequent mortalityDay 1PatientsAmiodarone
2006
Contemporary performance of surgical ventricular restoration procedures: Data from the Society of Thoracic Surgeons' National Cardiac Database
Hernandez AF, Velazquez EJ, Dullum MK, O'Brien SM, Ferguson TB, Peterson ED. Contemporary performance of surgical ventricular restoration procedures: Data from the Society of Thoracic Surgeons' National Cardiac Database. American Heart Journal 2006, 152: 494-499. PMID: 16923420, DOI: 10.1016/j.ahj.2006.01.016.Peer-Reviewed Original ResearchConceptsSurgical ventricular restorationNational Cardiac DatabaseThoracic Surgeons National Cardiac DatabaseSVR procedureCardiac DatabaseSurgical ventricular restoration proceduresAdverse procedural outcomesVentricular restoration proceduresCombined end pointSevere mitral insufficiencyLeft ventricular dysfunctionCongestive heart failureInsulin-dependent diabetesStatus of surgeryCombined deathMajor morbidityOperative mortalityVentricular dysfunctionBaseline characteristicsOperative riskRenal failureCoronary diseaseHeart failureMajor complicationsOperative outcomesGeographic variation in the treatment of acute myocardial infarction in the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial
Reed SD, McMurray JJ, Velazquez EJ, Schulman KA, Califf RM, Kober L, Maggioni AP, Van de Werf F, White HD, Diaz R, Mareev V, Murin J, Committees and Investigators F. Geographic variation in the treatment of acute myocardial infarction in the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial. American Heart Journal 2006, 152: 500-508. PMID: 16923421, DOI: 10.1016/j.ahj.2006.02.032.Peer-Reviewed Original ResearchConceptsHigh-risk patientsAcute myocardial infarctionMyocardial infarctionReperfusion therapyBaseline characteristicsVALIANT trialLeft ventricular systolic dysfunctionTime of MIAcute Myocardial Infarction trialSafety of captoprilMyocardial Infarction trialPatient baseline characteristicsUse of aspirinVentricular systolic dysfunctionProportion of patientsCare of patientsEvidence-based therapiesMultivariable regression modelsSystolic dysfunctionHeart failureTrial populationKey treatmentPatientsInternational trialInternational guidelines
2005
Left Ventricular Assessment in Myocardial Infarction: The VALIANT Registry
Hernandez AF, Velazquez EJ, Solomon SD, Kilaru R, Diaz R, O’Connor C, Ertl G, Maggioni AP, Rouleau JL, van Gilst W, Pfeffer MA, Califf RM. Left Ventricular Assessment in Myocardial Infarction: The VALIANT Registry. JAMA Internal Medicine 2005, 165: 2162-2169. PMID: 16217008, DOI: 10.1001/archinte.165.18.2162.Peer-Reviewed Original ResearchConceptsHeart failureMyocardial infarctionLV assessmentCardiac catheterizationVentricular assessmentAcute Myocardial Infarction RegistryAngiotensin-converting enzyme inhibitorClinical heart failureMyocardial Infarction RegistryLeft ventricular functionAcute myocardial infarctionQuality of careHospital mortalityHospital outcomesHospital stayBaseline characteristicsDischarge medicationsVentricular functionMultivariable modelPatientsPropensity analysisEnzyme inhibitorsLower mortalityCatheterizationEchocardiographyHeart failure on admission and the risk of stroke following acute myocardial infarction: the VALIANT registry
Szummer KE, Solomon SD, Velazquez EJ, Kilaru R, McMurray J, Rouleau JL, Mahaffey KW, Maggioni AP, Califf RM, Pfeffer MA, White HD. Heart failure on admission and the risk of stroke following acute myocardial infarction: the VALIANT registry. European Heart Journal 2005, 26: 2114-2119. PMID: 15972293, DOI: 10.1093/eurheartj/ehi352.Peer-Reviewed Original ResearchConceptsRisk of strokeHeart failureAcute myocardial infarctionMyocardial infarctionHospital strokeStroke riskOdds ratioAcute Myocardial Infarction RegistryPresence of HFConsecutive MI patientsKillip class IIIPrior heart failureHistory of hypertensionHistory of strokeMyocardial Infarction RegistryHospital mortalityKillip classBaseline characteristicsDismal prognosisMI patientsRisk factorsPatientsAdmissionClass IIIStroke
2004
Newly Diagnosed and Previously Known Diabetes Mellitus and 1-Year Outcomes of Acute Myocardial Infarction
Aguilar D, Solomon SD, Køber L, Rouleau JL, Skali H, McMurray JJ, Francis GS, Henis M, O’Connor C, Diaz R, Belenkov YN, Varshavsky S, Leimberger JD, Velazquez EJ, Califf RM, Pfeffer MA. Newly Diagnosed and Previously Known Diabetes Mellitus and 1-Year Outcomes of Acute Myocardial Infarction. Circulation 2004, 110: 1572-1578. PMID: 15364810, DOI: 10.1161/01.cir.0000142047.28024.f2.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngiotensin II Type 1 Receptor BlockersAngiotensin-Converting Enzyme InhibitorsCaptoprilCohort StudiesComorbidityDiabetes ComplicationsDiabetes MellitusDrug Therapy, CombinationFemaleFollow-Up StudiesHeart FailureHumansLife TablesMaleMedical RecordsMiddle AgedMulticenter Studies as TopicMyocardial InfarctionProportional Hazards ModelsRandomized Controlled Trials as TopicRiskStrokeTetrazolesTime FactorsTreatment OutcomeValineValsartanVentricular Dysfunction, LeftConceptsAcute myocardial infarctionMyocardial infarctionCardiovascular eventsDiabetes mellitusAdverse outcomesAcute Myocardial Infarction trialPoor long-term outcomesMajor cardiovascular eventsMyocardial Infarction trialHigh-risk patientsRisk of deathLong-term outcomesRisk of mortalityBaseline characteristicsDiabetic statusComorbid conditionsMetabolic abnormalitiesPrior diagnosisPoor prognosisNew diagnosisDiabetesPatientsMellitusOutcomesInfarction